Biologics Market Size (2024 - 2029)

Biologics Market Analysis

The Biologics Market size is estimated at USD 373.5 billion in 2024, and is expected to reach USD 615 billion by 2029, growing at a CAGR of 10.49% during the forecast period (2024-2029).

The Biopharmaceutical industry is majorly driven by growing capital investment from key players, the rise in the burden of chronic diseases, the loss of patent exclusivity of leading Biological drugs, and the increasing demand for and higher acceptability of innovative therapies.

According to the WHO report published in September 2023, non-communicable diseases (NCDs) cause 41 million deaths yearly, which is equivalent to 74% of the total death rate. Annually, 17 million individuals succumb to non-communicable diseases (NCDs) before reaching the age of 70, with a substantial 86% of these premature fatalities concentrated in low- and middle-income countries. A predominant 77% of NCD-related deaths occur within the same demographic. The primary contributors to NCD mortality are cardiovascular diseases, claiming 17.9 million lives each year, trailed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including diabetes-induced kidney disease deaths). Collectively, these four disease categories contribute to over 80% of all premature NCD deaths. Factors such as tobacco use, physical inactivity, harmful alcohol consumption, unhealthy dietary practices, and air pollution significantly elevate the risk of succumbing to NCDs. The increasing cases of chronic diseases are expected to increase the demand for biologics further in treating chronic diseases.

The Biologics market growth is fueled in part by increased investments. In October 2023, Syngene International, a subsidiary of Biocon Ltd, unveiled an annual investment plan surpassing USD 100 million, focusing primarily on advancing research, biologics, and small molecules, signaling significant commitment to the Biotechnology industry. Over the past five years, the company has committed a cumulative investment of approximately USD 54 million (INR 4,500 crores).

Furthermore, in March 2023, Teva, one of the Largest Biopharmaceutical Companies, made a substantial investment exceeding USD 1 billion in biologics in Europe. Recognizing the escalating demand for Biopharmaceuticals products, Teva has allocated funds to enhance biologics production technologies, specifically for Active Pharmaceutical Ingredients (APIs) involving cells for Biosimilars and novel biologics. Teva's robust pipeline encompasses biosimilars and novel biologic products across various therapeutic areas, and it is poised for delivery to patients in the coming years. At present, biotech products available in the market are manufactured within Teva's biologics production facilities in Ulm, Germany, and Vilnius, Lithuania, as well as through collaborations with external entities in Asia and the US, indicating its significant presence in the Global Biologics Market.

In addition, rising research and development activities in biologics support the Biologics market growth. For instance, in March 2023, Catalent, a leading Biopharmaceutical Research Company, signed a licensing agreement with Bhami Research Laboratory (BRL) based in India. This strategic collaboration grants Catalent access to BRL's advanced formulation technology. The primary objective for Catalent is to leverage this technology to facilitate the development of formulations, enabling the subcutaneous administration of high-concentration biologics. This empowers Catalent to engage in collaborative assessments with its clients, exploring the potential of BRL's formulation technology to reduce viscosity and enhance the delivery of high-concentration biologic products. BRL's technology exhibits versatility, applying various Monoclonal Antibodies and fusion proteins. Successful outcomes from this collaboration may lead to integrating these programs into Catalent's comprehensive formulation and manufacturing services on a larger scale.

Furthermore, Biologics market growth is anticipated to be driven by biologics product launches from key market players. For instance, in July 2023, Biocon Biologics officially announced the availability of HULIO (adalimumab-fkjp) injection, a Biosimilar to Humira (adalimumab), for patients in the United States. This milestone follows five years of successful experience with HULIO in Europe and another two years in Canada. The introduction of HULIO to the US market represents a significant expansion of its global presence. It offers patients in the United States access to a well-established and proven biosimilar option.

Moreover, in July 2022, Brii Biosciences Limited, in collaboration with TSB Therapeutics (Beijing) Co. Ltd, a majority-owned joint venture, officially launched the commercial availability of the amubarvimab/romlusevimab combination in China. The release of the initial commercial batch of these long-acting COVID-19 neutralizing antibodies on July 7 signified a significant achievement in advancing the commercialization of this innovative combination therapy.

Thus, the above-mentioned factors are anticipated to drive the Biologics industry's growth during the next five years. However, the stringent regulatory processes, high capital investment, and loss of patent exclusivity are likely to restrain the Biopharmaceutical industry growth.

Biologics Industry Segmentation

The term "biologics" refers to large, complex molecules made in living cells grown in a laboratory. Biologic medicines are often 200 to 1,000 times the size of a small molecule or chemical drug. Due to their large molecular size and fragile molecular structure, biologics are majorly delivered through parenteral routes. 

The biologics industry report is segmented by product, application, source, and geography. The product is further segmented into monoclonal antibodies, vaccines, recombinant hormones/proteins, cellular-based biologics, gene-based biologics, and other products. The application is divided into cancer, infectious, autoimmune, and other applications. The source is further bifurcated into microbial and mammalian. Geography segmented is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The biologics report also covers the estimated market size and trends for 17 countries across major global regions. The report offers the biologics market size and forecasts in value in USD for all the above-mentioned segments.